000			01928 a2200505 4500
005			20250516090710.0
264		0	_c20130312
008			201303s 0 0 eng d
022			_a1468-2060
024	7		_a10.1136/annrheumdis-2011-201108 _2doi
040			_aNLM _beng _cNLM
100	1		_aGalloway, James B
245	0	0	_aRisk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. _h[electronic resource]
260			_bAnnals of the rheumatic diseases _cFeb 2013
300			_a229-34 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdalimumab
650	0	4	_aAntibodies, Monoclonal _xadverse effects
650	0	4	_aAntibodies, Monoclonal, Humanized _xadverse effects
650	0	4	_aAntirheumatic Agents _xadverse effects
650	0	4	_aArthritis, Rheumatoid _xdrug therapy
650	0	4	_aEtanercept
650	0	4	_aHerpes Zoster _xepidemiology
650	0	4	_aHumans
650	0	4	_aImmunoglobulin G _xadverse effects
650	0	4	_aIncidence
650	0	4	_aInfliximab
650	0	4	_aMiddle Aged
650	0	4	_aReceptors, Tumor Necrosis Factor
650	0	4	_aRisk Factors
650	0	4	_aSkin Diseases, Infectious _xepidemiology
650	0	4	_aSoft Tissue Infections _xepidemiology
650	0	4	_aTumor Necrosis Factor-alpha _xantagonists & inhibitors
700	1		_aMercer, Louise K
700	1		_aMoseley, Alison
700	1		_aDixon, William G
700	1		_aUstianowski, Andrew P
700	1		_aHelbert, Matthew
700	1		_aWatson, Kath D
700	1		_aLunt, Mark
700	1		_aHyrich, Kimme L
700	1		_aSymmons, Deborah Pm
773	0		_tAnnals of the rheumatic diseases _gvol. 72 _gno. 2 _gp. 229-34
856	4	0	_uhttps://doi.org/10.1136/annrheumdis-2011-201108 _zAvailable from publisher's website
999			_c21730701 _d21730701